TVM Capital - Investor Profile and Portfolio

Actelion specializes in small molecule therapeutics for orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases: Tracleer (bosentan), a dual endothelin receptor antagonist which was the first oral treatment approved for pulmonary arterial hypertension; Zavesca (miglustat), currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Ventavis (iloprost), indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms; Veletri (epoprostenol for injection), approved for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.